Journal of the Association of Nurses in AIDS Care
Volume 21, Issue 1 , Pages 63-74 , January 2010

Hepatitis C Treatment Experiences and Decision Making Among Patients Living With HIV Infection

References 

  1. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. Journal of Hepatology. 2005;42:615–624
  2. Alter MJ. Epidemiology of Hepatitis C. Hepatology. 1997;26(Suppl.):62S–65S
  3. Bandura A. Social foundations of thought and action: A social cognitive theory. Englewood Cliffs, NJ: Prentice-Hall; 1986;
  4. Benhamou Y, Bochet M, DiMartino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology. 1999;30:1054–1058
  5. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clinical Infectious Diseases. 2001;32:492–497
  6. Bova C, Jaffarian C, Himlan P, Mangini L, Ogawa L. The symptom experience of HIV/hepatitis C virus-coinfected adults. Journal of the Association of Nurses in AIDS Care. 2008;19:170–180
  7. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs. standard interferon alfa-2b plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. Journal of the American Medical Association. 2004;292:2839–2848
  8. Centers for Disease Control and Prevention. The 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report. 1992;41(RR-17):
  9. Chung R, Andersen J, Volberding PA, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. New England Journal of Medicine. 2004;351:451–459
  10. Dieterich DT. Hepatitis C infection in HIV. AIDS Patient Care and STDS. 2004;18:127–130
  11. Glaser BG, Strauss AL. The discovery of grounded theory: Strategies for qualitative research. Chicago: Aldine; 1967;
  12. Grow JM, Christopher SA. Breaking the silence surrounding Hepatitis C by promoting self-efficacy: Hepatitis C public service announcements. Qualitative Health Research. 2008;18:1401–1412
  13. Highleyman L. Focus on hepatitis. Final APRICOT, ACTG A5071 results. International Association of Physicians in AIDS Care Monthly. 2004;10:356–357
  14. Khokhar OS, Lewis JH. Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: Do they alter their decision with time?. Digestive Disease Science. 2006;52:1168–1176
  15. Lazarus RS, Folkman S. Stress, appraisal and coping. New York: Springer; 1984;
  16. Lincoln YS, Guba EG. Naturalistic inquiry. Thousand Oaks, CA: Sage; 1985;
  17. Lo Re V, Kostman JR, Amorosa VK. Management of complexities of HIV/hepatitis C virus coinfection in the twenty-first century. Clinics in Liver Disease. 2008;12:587–609
  18. McNally S, Temple-Smith M, Sievert W, Pitts MK. Now, later or never? Challenges associated with hepatitis C treatment. Australian and New Zealand Journal of Public Health. 2006;30:422–427
  19. Mehta SH, Lucas GM, Mirel LB, Torbenson M, Higgins Y, Moore RD, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS. 2006;20:2361–2369
  20. Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk G, Vlahov D, et al. Limited uptake of hepatitis C treatment among injection drug users. Journal of Community Health. 2008;33:126–133
  21. Mehta SH, Thomas DL, Sulkowski M, Safaein M, Vlahov D, Strathdee SA. A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV co-infected injection drug users. AIDS. 2005;19(Suppl. 3):S179–S189
  22. Miles MB, Huberman AM. Qualitative data analysis: An expanded sourcebook. Thousand Oaks, CA: Sage; 1994;
  23. Mohsen AH, Easterbrook PJ, Taylor C, Portmann B, Kulasegarem R, Murad S, et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut. 2003;52:1035–1040
  24. Ogawa LF, Bova C. Substance use experiences and hepatitis C treatment decision-making among HIV/HCV coinfected adults. Substance Use & Misuse. 2009;44:915–933
  25. Patton M. Qualitative evaluation and research methods. Thousand Oaks, CA: Sage; 1990;
  26. Puoti M, Bonacini M, Spinetti A, Putzolu V, Govindariajan S, Zaltron S, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. Journal of Infectious Diseases. 2001;183:134–137
  27. Rifai MA. Ethical impasses in the care of patients with hepatitis C. Psychosomatics. 2006;47:540–541
  28. Sandelowski M. Whatever happened to qualitative description?. Research in Nursing and Health. 2000;23:334–340
  29. Schackman BR, Teixeira PA, Weitzman G, Mushlin AI, Jacobson IM. Quality of life tradeoffs for hepatitis C treatment: Do patients and providers agree?. Medical Decision-Making. 2008;28:233–242
  30. Selik RM, Byers RH, Dworkin MS. Trends in diseases reported in U.S. death certificates that mentioned HIV infection, 1987-1999. Journal of Acquired Immune Deficiency Syndromes. 2002;29:378–387
  31. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US Adults AIDS Clinical Trials Group. Clinical Infectious Diseases. 2002;34:831–837
  32. Strathdee SA, Patterson TL. Behavioral interventions for HIV-positive and HCV-positive drug users. AIDS and Behavior. 2006;10:115–130
  33. Sulkowski M, Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. Journal of Viral Hepatitis. 2007;14:371–386
  34. Sulkowski M, Thomas DL. Hepatitis C in the HIV-infected person. Annals of Internal Medicine. 2003;128:197–207
  35. Sulkowski M, Thomas DL. Epidemiology and natural history of hepatitis C virus infection in injection drug users: Implications for treatment. Clinical Infectious Diseases. 2005;40(Suppl. 5):S263–S269
  36. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE. Hepatitis C and progression of HIV disease. Journal of the American Medical Association. 2002;288:199–206
  37. Sullivan-Bolyai S, Bova C, Harper D. Developing and refining interventions in persons with health disparities: The use of qualitative description. Nursing Outlook. 2005;53:127–133
  38. Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology. 2002;36:S201–S209
  39. Thomas DL. The challenge of hepatitis C in the HIV-infected person. Annual Review of Medicine. 2008;59:473–485
  40. Torriani FJ, Rodriguez-Torres M, Rockstroh J, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New England Journal of Medicine. 2004;351:438–450
  41. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr W, Kirk O, et al. Liver-related deaths in persons infected with human immunodeficiency virus. Archives of Internal Medicine. 2006;166:1632–1641
  42. Zylberger H, Pol S. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Clinical Infectious Diseases. 1996;23:1117–1125

PII: S1055-3290(09)00157-5

doi: 10.1016/j.jana.2009.07.009

Journal of the Association of Nurses in AIDS Care
Volume 21, Issue 1 , Pages 63-74 , January 2010

Article Tools

* Image Usage & Resolution